Moderna reports promising results for first therapeutic melanoma vaccine at European oncology congress

During the European Society of Oncology congress in Madrid, Moderna unveiled trial results indicating its experimental vaccine can treat melanoma, a first for therapeutic cancer vaccines. The findings, which had been partially leaked in August, are expected to enable the firm to file for regulatory approval in the near future. Édith Borcoman, an oncologist at Institut Curie in Paris, described the achievement as a major technological feat and highlighted the prospect of scaling vaccine manufacturing for regular use.

While preventive vaccines such as the HPV shot protect against certain cancers, this development represents a decade-long research effort that finally delivered a positive outcome after many setbacks. The announcement has generated optimism that similar therapeutic vaccines could be developed for other tumor types.